Get the Stockscreener App
101.38
0.12%
0.12
After Hours:
99.71
-1.67
-1.65%
Axsome Therapeutics Inc stock is traded at $101.38, with a volume of 781.74K.
It is up +0.12% in the last 24 hours and down -2.88% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$101.26
Open:
$102.145
24h Volume:
781.74K
Relative Volume:
1.23
Market Cap:
$4.99B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-15.53
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-3.42%
1M Performance:
-2.88%
6M Performance:
-4.77%
1Y Performance:
+16.11%
1-Day Range:
$101.22
$103.49
1-Week Range:
$99.38
$105.86
52-Week Range:
$72.21
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
101.38 | 4.99B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Royce & Associates LP Lowers Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 50,096 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (AXSM) Projected to Post Quarterly Earnings on Monday - MarketBeat
Knights of Columbus Asset Advisors LLC Has $1.86 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
News impact scoring models applied to Axsome Therapeutics Inc.Pattern Breakout Entry Stock Forecast in Focus - metal.it
Axsome Therapeutics and Viking Therapeutics: Biotech Stocks to WatchNews and Statistics - IndexBox
2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% - inkl
Key External Factors That Drive Axsome Therapeutics Inc. Stock Price MovementsEarnings Play Trade Plan With Alerts Shared - metal.it
Axsome Therapeutics Inc. Recovery Hinges on Volume BreakoutStock Market Entry Timing Signals Revealed - metal.it
Axsome Therapeutics Inc.’s Price Action Aligns with Quant SignalsTriple Digit Return Stock Predictions Released - metal.it
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
What makes Axsome Therapeutics Inc. stock price move sharplyStock Strategy Planner To Watch Now - jammulinksnews.com
Envestnet Asset Management Inc. Has $2.92 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Why is Axsome Therapeutics Inc. stock attracting strong analyst attentionAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
Is Axsome Therapeutics Inc. stock overvalued or undervaluedFree Investment Case Studies - jammulinksnews.com
What catalysts could drive Axsome Therapeutics Inc. stock higher in 2025Invest confidently with real-time data analysis - jammulinksnews.com
Does Axsome Therapeutics Inc. stock perform well during market downturnsGet timely alerts on market opportunities - jammulinksnews.com
Cwm LLC Trims Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Y Intercept Hong Kong Ltd Makes New $1.49 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Stock Market Query - metal.it
What is Axsome Therapeutics Inc. company’s growth strategyUnstoppable profit momentum - jammulinksnews.com
When is Axsome Therapeutics Inc. stock expected to show significant growthConsistent triple returns - jammulinksnews.com
How strong is Axsome Therapeutics Inc. company’s balance sheetFree Market Dynamics Reports - jammulinksnews.com
Published on: 2025-07-27 23:41:07 - jammulinksnews.com
How does Axsome Therapeutics Inc. generate profit in a changing economyUnprecedented profit potential - jammulinksnews.com
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.6%Here's Why - MarketBeat
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today - 富途牛牛
Axsome Therapeutics: Navigating Setbacks with a Strong Pipeline and Analyst Confidence - AInvest
Axsome: Some Recent Setbacks, Some Recent Wins — Still A Buy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - ADVFN Brasil
Why Axsome Therapeutics Inc. stock is on top investor watchlistsSuperior stock selection - jammulinksnews.com
What analysts say about Axsome Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
Axsome Therapeutics Inc. Stock Analysis and ForecastRapid growth trajectories - PrintWeekIndia
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
New York State Common Retirement Fund Has $3.92 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is Axsome Therapeutics Inc. stock overhyped or has real potentialUnstoppable trading performance - jammulinksnews.com
How high can Axsome Therapeutics Inc. stock price go in 2025Breakthrough investment results - jammulinksnews.com
How To Trade (AXSM) - news.stocktradersdaily.com
Axsome Therapeutics Settles SUNOSI (Solriamfetol) Patent Litigation With Hetero Labs Ltd. - 富途牛牛
Is This Stock a Buy After Soaring by 20% in 1 Day? - AOL.com
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - MSN
Q3 EPS Estimate for Axsome Therapeutics Raised by Analyst - MarketBeat
Legato Capital Management LLC Acquires New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is Axsome Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):